Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David van Duin

Showing results (11-20 of 204) with videos related to

Pageof 21
Sort By:
Infectious Disease Clinics of North America|October 4, 2020
Multidrug-Resistant Bacteria in the Community: An UpdateDavid van Duin, David L Paterson
The Lancet. Infectious Diseases|February 1, 2017
China's antibiotic resistance problemsDavid L Paterson, David van Duin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Reply to Macesic et alDavid van Duin, Robert A Bonomo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2016
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsDavid van Duin, Robert A Bonomo
JAMA|July 17, 2025
What Is Antimicrobial Resistance?Cesar A Arias, David van Duin
F1000Research|February 23, 2019
Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteriaRichard R Watkins, David Van Duin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 10, 2018
Reply to Elamin et alAnne M Lachiewicz, David van Duin
Journal of the American Geriatrics Society|September 5, 2007
Toll-like receptors in older adultsDavid van Duin, Albert C Shaw
Infectious Disease Clinics of North America|May 22, 2016
Multidrug-Resistant Bacteria in the Community: Trends and Lessons LearnedDavid van Duin, David L Paterson
Antimicrobial Agents and Chemotherapy|August 23, 2021
Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii InfectionsJessica Howard-Anderson, David van Duin
Pageof 21

Showing results (11-20 of 204) with videos related to

Sort By:
Pageof 21
Infectious Disease Clinics of North America|October 4, 2020
Multidrug-Resistant Bacteria in the Community: An UpdateDavid van Duin, David L Paterson
The Lancet. Infectious Diseases|February 1, 2017
China's antibiotic resistance problemsDavid L Paterson, David van Duin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 12, 2017
Reply to Macesic et alDavid van Duin, Robert A Bonomo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 22, 2016
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor CombinationsDavid van Duin, Robert A Bonomo
JAMA|July 17, 2025
What Is Antimicrobial Resistance?Cesar A Arias, David van Duin
F1000Research|February 23, 2019
Current trends in the treatment of pneumonia due to multidrug-resistant Gram-negative bacteriaRichard R Watkins, David Van Duin
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 10, 2018
Reply to Elamin et alAnne M Lachiewicz, David van Duin
Journal of the American Geriatrics Society|September 5, 2007
Toll-like receptors in older adultsDavid van Duin, Albert C Shaw
Infectious Disease Clinics of North America|May 22, 2016
Multidrug-Resistant Bacteria in the Community: Trends and Lessons LearnedDavid van Duin, David L Paterson
Antimicrobial Agents and Chemotherapy|August 23, 2021
Case Commentary: Uncertainty in Evaluating Treatment Outcomes in Carbapenem-Resistant Acinetobacter baumannii InfectionsJessica Howard-Anderson, David van Duin
Pageof 21